These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

325 related articles for article (PubMed ID: 36104175)

  • 1. The Impact of Antiviral Therapy for Hepatitis C Virus on the Survival of Patients after Hepatocellular Carcinoma Treatment.
    Mori Y; Matsuda S; Sato M; Muraoka M; Suzuki Y; Tatsumi A; Nakayama Y; Inoue T; Maekawa S; Enomoto N
    Intern Med; 2022; 61(18):2721-2729. PubMed ID: 36104175
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficacy of hepatitis C virus eradication after curative treatment for hepatocellular carcinoma in patients with advanced hepatocellular carcinoma and decreased hepatic functional reserve: A nationwide, multicentre study by the Japanese Red Cross Liver Study Group.
    Mashiba T; Joko K; Kurosaki M; Ochi H; Marusawa H; Uchida Y; Fujii H; Kojima Y; Yoshida H; Goto T; Akahane T; Kondo M; Tsuji K; Mitsuda A; Hasebe C; Kusakabe A; Sohda T; Furuta K; Kobashi H; Ogawa C; Ide Y; Arai H; Okada K; Shigeno M; Nonogi R; Izumi N
    J Viral Hepat; 2022 Jul; 29(7):551-558. PubMed ID: 35548866
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The influence of direct-acting antivirals in hepatitis C virus related hepatocellular carcinoma after curative treatment.
    Kuo YH; Wang JH; Chang KC; Hung CH; Lu SN; Hu TH; Yen YH; Kee KM; Chen CH
    Invest New Drugs; 2020 Feb; 38(1):202-210. PubMed ID: 31701431
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Direct-acting antivirals after successful treatment of early hepatocellular carcinoma improve survival in HCV-cirrhotic patients.
    Cabibbo G; Celsa C; Calvaruso V; Petta S; Cacciola I; Cannavò MR; Madonia S; Rossi M; Magro B; Rini F; Distefano M; Larocca L; Prestileo T; Malizia G; Bertino G; Benanti F; Licata A; Scalisi I; Mazzola G; Di Rosolini MA; Alaimo G; Averna A; Cartabellotta F; Alessi N; Guastella S; Russello M; Scifo G; Squadrito G; Raimondo G; Trevisani F; Craxì A; Di Marco V; Cammà C;
    J Hepatol; 2019 Aug; 71(2):265-273. PubMed ID: 30959157
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Hepatocellular carcinoma, decompensation, and mortality based on hepatitis C treatment: A prospective cohort study.
    Choi GH; Jang ES; Kim YS; Lee YJ; Kim IH; Cho SB; Lee HC; Jang JW; Ki M; Choi HY; Baik D; Jeong SH
    World J Gastroenterol; 2022 Aug; 28(30):4182-4200. PubMed ID: 36157119
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cure With Interferon-Free Direct-Acting Antiviral Is Associated With Increased Survival in Patients With Hepatitis C Virus-Related Hepatocellular Carcinoma From Both East and West.
    Dang H; Yeo YH; Yasuda S; Huang CF; Iio E; Landis C; Jun DW; Enomoto M; Ogawa E; Tsai PC; Le A; Liu M; Maeda M; Nguyen B; Ramrakhiani N; Henry L; Cheung R; Tamori A; Kumada T; Tanaka Y; Yu ML; Toyoda H; Nguyen MH
    Hepatology; 2020 Jun; 71(6):1910-1922. PubMed ID: 31610027
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Incidence of Hepatocellular Carcinoma in Patients With HCV-Associated Cirrhosis Treated With Direct-Acting Antiviral Agents.
    Calvaruso V; Cabibbo G; Cacciola I; Petta S; Madonia S; Bellia A; Tinè F; Distefano M; Licata A; Giannitrapani L; Prestileo T; Mazzola G; Di Rosolini MA; Larocca L; Bertino G; Digiacomo A; Benanti F; Guarneri L; Averna A; Iacobello C; Magro A; Scalisi I; Cartabellotta F; Savalli F; Barbara M; Davì A; Russello M; Scifo G; Squadrito G; Cammà C; Raimondo G; Craxì A; Di Marco V;
    Gastroenterology; 2018 Aug; 155(2):411-421.e4. PubMed ID: 29655836
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Hepatocellular carcinoma decreases the chance of successful hepatitis C virus therapy with direct-acting antivirals.
    Prenner SB; VanWagner LB; Flamm SL; Salem R; Lewandowski RJ; Kulik L
    J Hepatol; 2017 Jun; 66(6):1173-1181. PubMed ID: 28161470
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effectiveness of direct acting antiviral agents for hepatitis C virus related recurrent hepatocellular carcinoma patients who had multiple courses of recurrence.
    Ohki T; Sato K; Kondo M; Goto E; Sato T; Kondo Y; Akamatsu M; Sato S; Yoshida H; Koike Y; Obi S
    J Viral Hepat; 2021 Nov; 28(11):1597-1603. PubMed ID: 34312954
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The impact of interferon-free direct-acting antivirals on clinical outcome after curative treatment for hepatitis C virus-associated hepatocellular carcinoma: Comparison with interferon-based therapy.
    Nagaoki Y; Imamura M; Nishida Y; Daijo K; Teraoka Y; Honda F; Nakamura Y; Morio K; Fujino H; Nakahara T; Kawaoka T; Tsuge M; Hiramatsu A; Kawakami Y; Miki D; Hiyama Y; Ochi H; Chayama K; Aikata H
    J Med Virol; 2019 Apr; 91(4):650-658. PubMed ID: 30381831
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical outcomes following DAA therapy in patients with HCV-related cirrhosis depend on disease severity.
    Krassenburg LAP; Maan R; Ramji A; Manns MP; Cornberg M; Wedemeyer H; de Knegt RJ; Hansen BE; Janssen HLA; de Man RA; Feld JJ; van der Meer AJ
    J Hepatol; 2021 May; 74(5):1053-1063. PubMed ID: 33242501
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Reduction of the Risk of Hepatocellular Carcinoma over Time Using Direct-Acting Antivirals: A Propensity Score Analysis of a Real-Life Cohort (PITER HCV).
    Quaranta MG; Cavalletto L; Russo FP; Calvaruso V; Ferrigno L; Zanetto A; Mattioli B; D'Ambrosio R; Panetta V; Brancaccio G; Raimondo G; Brunetto MR; Zignego AL; Coppola C; Iannone A; Biliotti E; Rosselli Del Turco E; Massari M; Licata A; Barbaro F; Persico M; Morisco F; Pompili M; Cerini F; Puoti M; Santantonio T; Craxì A; Kondili LA; Chemello L; On Behalf Of Piter Collaborating Investigators
    Viruses; 2024 Apr; 16(5):. PubMed ID: 38793565
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Changes in clinical outcomes in Japanese patients with hepatocellular carcinoma due to hepatitis C virus following the development of direct-acting antiviral agents.
    Ohama H; Hiraoka A; Tada T; Kariyama K; Itobayashi E; Tsuji K; Ishikawa T; Toyoda H; Hatanaka T; Kakizaki S; Naganuma A; Tada F; Tanaka H; Nakamura S; Nouso K; Tanaka K; Kumada T;
    J Gastroenterol Hepatol; 2024 Jul; 39(7):1394-1402. PubMed ID: 38602340
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Sustained virologic response to direct-acting antiviral therapy in patients with chronic hepatitis C and hepatocellular carcinoma: A systematic review and meta-analysis.
    Ji F; Yeo YH; Wei MT; Ogawa E; Enomoto M; Lee DH; Iio E; Lubel J; Wang W; Wei B; Ide T; Preda CM; Conti F; Minami T; Bielen R; Sezaki H; Barone M; Kolly P; Chu PS; Virlogeux V; Eurich D; Henry L; Bass MB; Kanai T; Dang S; Li Z; Dufour JF; Zoulim F; Andreone P; Cheung RC; Tanaka Y; Furusyo N; Toyoda H; Tamori A; Nguyen MH
    J Hepatol; 2019 Sep; 71(3):473-485. PubMed ID: 31096005
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Human Immunodeficiency Virus (HIV) Infection Is Associated With Lower Risk of Hepatocellular Carcinoma After Sustained Virological Response to Direct-acting Antivirals in Hepatitis C Infected Patients With Advanced Fibrosis.
    Corma-Gómez A; Macías J; Lacalle-Remigio JR; Téllez F; Morano L; Rivero A; Serrano M; Ríos MJ; Vera-Méndez FJ; Alados JC; Real LM; Palacios R; Santos IL; Imatz A; Pineda JA;
    Clin Infect Dis; 2021 Oct; 73(7):e2109-e2116. PubMed ID: 32766891
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Surgical outcomes for hepatocellular carcinoma detected after hepatitis C virus eradiation by direct-acting antivirals.
    Tanaka S; Shinkawa H; Tamori A; Takemura S; Takahashi S; Amano R; Kimura K; Ohira G; Kawada N; Kubo S
    J Surg Oncol; 2020 Dec; 122(8):1543-1552. PubMed ID: 32856301
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Direct-Acting Antiviral Therapy for Hepatitis C Virus in Patients with BCLC Stage B/C Hepatocellular Carcinoma.
    Lee SW; Chen LS; Yang SS; Huang YH; Lee TY
    Viruses; 2022 Oct; 14(11):. PubMed ID: 36366415
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Hepatitis C Virus Cure Rates Are Reduced in Patients With Active but Not Inactive Hepatocellular Carcinoma: A Practice Implication.
    Ogawa E; Toyoda H; Iio E; Jun DW; Huang CF; Enomoto M; Hsu YC; Haga H; Iwane S; Wong G; Lee DH; Tada T; Liu CH; Chuang WL; Hayashi J; Cheung R; Yasuda S; Tseng CH; Takahashi H; Tran S; Yeo YH; Henry L; Barnett SD; Nomura H; Nakamuta M; Dai CY; Huang JF; Yang HI; Lee MH; Jun MJ; Kao JH; Eguchi Y; Ueno Y; Tamori A; Furusyo N; Yu ML; Tanaka Y; Nguyen MH;
    Clin Infect Dis; 2020 Dec; 71(11):2840-2848. PubMed ID: 31777940
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Sustained virologic response to direct-acting antiviral agents predicts better outcomes in hepatitis C virus-infected patients: A retrospective study.
    Colussi G; Donnini D; Brizzi RF; Maier S; Valenti L; Catena C; Cavarape A; Sechi LA; Soardo G
    World J Gastroenterol; 2019 Oct; 25(40):6094-6106. PubMed ID: 31686765
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Direct-Acting Antiviral Therapy Not Associated With Recurrence of Hepatocellular Carcinoma in a Multicenter North American Cohort Study.
    Singal AG; Rich NE; Mehta N; Branch A; Pillai A; Hoteit M; Volk M; Odewole M; Scaglione S; Guy J; Said A; Feld JJ; John BV; Frenette C; Mantry P; Rangnekar AS; Oloruntoba O; Leise M; Jou JH; Bhamidimarri KR; Kulik L; Tran T; Samant H; Dhanasekaran R; Duarte-Rojo A; Salgia R; Eswaran S; Jalal P; Flores A; Satapathy SK; Wong R; Huang A; Misra S; Schwartz M; Mitrani R; Nakka S; Noureddine W; Ho C; Konjeti VR; Dao A; Nelson K; Delarosa K; Rahim U; Mavuram M; Xie JJ; Murphy CC; Parikh ND
    Gastroenterology; 2019 May; 156(6):1683-1692.e1. PubMed ID: 30660729
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.